A djuvant radiotherapy (RT) after radical prostatectomy did not improve outcomes in prostate cancer as compared with salvage ...

Two agents have been approved by the Food and Drug Administration (FDA) for adjuvant use after nephrectomy on the basis of a disease-free survival benefit observed in randomized, placebo ...

Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results ...

The global agricultural adjuvant market is forecast to expand at 6% CAGR over the forecast period, as per FMI’s analysis. The ...

Agricultural Activator Adjuvant Market set to hit worth US$ 6.6 billion at CAGR 4.9% during forecast period 2024 to 2034 ...

On 18 April 2024, the US Food and Drug Administration (FDA) approved Roche’s Alecensa (alectinib), an oral anaplastic ...

The approval was based on data from the phase 3 ALINA trial. The US Food and Drug Administration (FDA) has approved Alecensa (alectinib) as adjuvant treatment for adults with ALK-positive non-small ...

Much of Moderna’s focus is on nabbing FDA approval for a respiratory syncytial virus vaccine, a decision expected in a matter ...

Zoom in a little further and it’s evident that an innovative variation on the VMAT theme – known as tangential VMAT (tVMAT) – is similarly established as the go-to treatment modality for adjuvant ...

Recently published article reports the findings of a randomized clinical trial that investigated the impact of ultrasound-guided quadratus lumborum block (QLB) on analgesia and ...

The US Food and Drug Administration (FDA) has approved alectinib (Alecensa, Genentech) in the adjuvant setting following ...

Alectinib approved by US FDA for auxiliary treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small ...